Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?The Motley Fool • 06/11/26
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific SessionsGlobeNewsWire • 06/03/26
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/28/26
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor ConferenceGlobeNewsWire • 05/12/26
Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1Zacks Investment Research • 05/07/26
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical UpdatesGlobeNewsWire • 05/07/26
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules CapitalGlobeNewsWire • 05/04/26
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026GlobeNewsWire • 04/30/26
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual MeetingGlobeNewsWire • 04/17/26
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity DrugZacks Investment Research • 03/24/26
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & ExpoGlobeNewsWire • 03/24/26
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851GlobeNewsWire • 03/23/26
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for DiabetesGlobeNewsWire • 03/11/26
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical UpdatesGlobeNewsWire • 03/05/26
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor ConferencesGlobeNewsWire • 03/03/26
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026GlobeNewsWire • 02/26/26
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private PlacementGlobeNewsWire • 02/06/26
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private PlacementGlobeNewsWire • 01/30/26
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th AnniversaryGlobeNewsWire • 01/23/26
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic PainGlobeNewsWire • 01/21/26